| Reversal effects of hyaluronan oligosaccharides on adriamycin resistance of K562/A02 cells. | |
| | |
MedLine Citation:
|
PMID: 19606017 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
As the interaction of hyaluronan (HA) with its receptor CD44 contributes to multidrug resistance (MDR) of tumor cells, HA oligosaccharides (o-HAs), as HA antagonists, may be useful to reverse the MDR. The objective of this study was to investigate the reversal effects of four o-HAs, including 4 saccharide residue (o-HA4), 6 saccharide residue (o-HA6), 8 saccharide residue (o-HA8), and 10 saccharide residue (o-HA10) fragments, on adriamycin (ADR)-resistant K562/A02 cells. The four o-HAs were prepared by digesting the native high molecular weight HA with hyaluronidase and gel filtration chromatography. 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay was used to assess the cytotoxicity of the four o-HAs and/or ADR on K562/A02 and K562 cells. The intracellular accumulation of ADR in K562/A02 cells was measured by flow cytometry. By comparing the IC50 (concentration resulting in 50% inhibition of cell growth) of ADR with K562/A02 cells in the presence and absence of a series of different concentrations of o-HAs, the reversal folds of the four o-HAs were calculated. The reversal folds of o-HA4, o-HA6, o-HA8, and o-HA10 were 2.04, 2.05, 1.91, and 1.84, respectively. After o-HA4, o-HA6, o-HA8, and o-HA10 treatment, the intracellular amounts of ADR were increased to 3.90, 3.92, 3.76, and 3.39 times, respectively. Shorter o-HAs (o-HA4 and o-HA6) showed stronger reversal effects than longer o-HAs (o-HA8 and o-HA10). In conclusion, the results showed that the four o-HAs could effectively reverse the ADR resistance of K562/A02 cells by increasing the intracellular accumulation of ADR. O-HAs may be used as MDR reversal drugs to increase the effectiveness of chemotherapy. |
| | |
Authors:
|
Xiangzhen Cui; Shuai Zhou; Huanli Xu; Ting Zhao; Aihua Liu; Xueping Guo; Fengshan Wang |
Related Documents
:
|
8396937 - Altered topoisomerase i activity and recombination activating gene expression in a huma... 9766497 - Characterization of h+-atpase-dependent activity of multidrug resistance-associated pro... 1913627 - Differential expression of glycoproteins containing alpha-d-galactosyl groups on normal... 7913667 - P-glycoprotein expression in classical multi-drug resistant leukaemia cells does not co... 7576237 - Quantification of intracellular cathepsin activities in human lung tumor cell lines by ... 10878317 - A simple protocol to evaluate nitrogen utilisation in saccharomyces cerevisiae. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Anti-cancer drugs Volume: 20 ISSN: 1473-5741 ISO Abbreviation: Anticancer Drugs Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-09-03 Completed Date: 2009-12-31 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9100823 Medline TA: Anticancer Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 800-6 Citation Subset: IM |
Affiliation:
|
Institute of Biochemical and Biotechnological Drugs, School of Pharmaceutical Sciences, Shandong University, Shandong, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibiotics, Antineoplastic
/
pharmacokinetics,
pharmacology Cell Proliferation / drug effects Doxorubicin / pharmacokinetics, pharmacology* Drug Resistance, Neoplasm / drug effects* Drug Screening Assays, Antitumor Humans Hyaluronic Acid / analogs & derivatives*, chemistry K562 Cells Molecular Structure Oligosaccharides / chemical synthesis*, pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/Antibiotics, Antineoplastic; 0/Oligosaccharides; 23214-92-8/Doxorubicin; 9004-61-9/Hyaluronic Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Development and assessment of novel all-in-one parenteral formulations with integrated anticoagulant...
Next Document: Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor ...